We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2010 by Vanderbilt University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00178932
First Posted: September 15, 2005
Last Update Posted: November 3, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Vanderbilt University
September 12, 2005
September 15, 2005
November 3, 2010
November 1998
January 2012   (Final data collection date for primary outcome measure)
We plan to compare the polymorphisms across schizophrenic patients and adults who do not have a diagnosed major mental illness. . [ Time Frame: single visit ]
We plan to compare the polymorphisms across schizophrenic patients and adults who do not have a diagnosed major mental illness. .
Complete list of historical versions of study NCT00178932 on ClinicalTrials.gov Archive Site
We will also evaluate relationships between the polymorphism and past and current mental health among the non-diagnosed sample [ Time Frame: single visit ]
We will also evaluate relationships between the polymorphism and past and current mental health among the non-diagnosed sample
Not Provided
Not Provided
 
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.
Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
  • Schizophrenia
  • Schizoaffective Disorder
  • Bipolar Disorder
  • Major Depression
  • Procedure: genetic analysis
    genetic assay of blood sample drawn with patient's consent
  • Procedure: genetic assay
    genetic assay of blood sample drawn with patient's consent
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
1000
January 2012
January 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder.

Exclusion Criteria:

Patients with DSM-IV diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.

Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00178932
9132
No
Not Provided
Not Provided
Herbert Meltzer, M.D., Vanderbilt University Medical Center
Vanderbilt University
Not Provided
Principal Investigator: Herbert Y Meltzer, M.D. Vanderbilt University Medical Center
Vanderbilt University
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP